君实生物(01877)：特瑞普利单抗联合贝伐珠单抗一线治疗晚期肝细胞癌的新适应症上市申请获得受理

智通财经07-17

智通财经APP讯，君实生物(01877)公布，近日，公司收到国家药品监督管理局核准签发的《受理通知书》，特瑞普利单抗(商品名：拓益®)联合贝伐珠单抗用于不可切除或转移性肝细胞癌患者的一线治疗的新适应症上市申请获得受理。本次新适应症上市申请主要基于 HEPATORCH 研究(NCT04723004)，该研究是一项多中心、随机、开放、阳性药对照的 III 期临床研究，旨在评估与标准治疗索拉非尼相比，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2452156191?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-07-17 20:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2452156191","market":"hk","top_or_hot":-1,"title":"君实生物(01877)：特瑞普利单抗联合贝伐珠单抗一线治疗晚期肝细胞癌的新适应症上市申请获得受理","media":"智通财经","content":"<div>\n<p>智通财经APP讯，君实生物(01877)公布，近日，公司收到国家药品监督管理局核准签发的《受理通知书》，特瑞普利单抗(商品名：拓益®)联合贝伐珠单抗用于不可切除或转移性肝细胞癌患者的一线治疗的新适应症上市申请获得受理。本次新适应症上市申请主要基于 HEPATORCH 研究(NCT04723004)，该研究是一项多中心、随机、开放、阳性药对照的 III 期临床研究，旨在评估与标准治疗索拉非尼相比，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1152294.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>君实生物(01877)：特瑞普利单抗联合贝伐珠单抗一线治疗晚期肝细胞癌的新适应症上市申请获得受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n君实生物(01877)：特瑞普利单抗联合贝伐珠单抗一线治疗晚期肝细胞癌的新适应症上市申请获得受理\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-17 20:33 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1152294.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，君实生物(01877)公布，近日，公司收到国家药品监督管理局核准签发的《受理通知书》，特瑞普利单抗(商品名：拓益®)联合贝伐珠单抗用于不可切除或转移性肝细胞癌患者的一线治疗的新适应症上市申请获得受理。本次新适应症上市申请主要基于 HEPATORCH 研究(NCT04723004)，该研究是一项多中心、随机、开放、阳性药对照的 III 期临床研究，旨在评估与标准治疗索拉非尼相比，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1152294.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688180","symbol_name":"君实生物","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1152294.html","article_id":"2452156191","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2452156191","pubTimestamp":1721219586,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，君实生物 公布，近日，公司收到国家药品监督管理局核准签发的《受理通知书》，特瑞普利单抗联合贝伐珠单抗用于不可切除或转移性肝细胞癌患者的一线治疗的新适应症上市申请获得受理。研究结果显示，特瑞普利单抗联合贝伐珠单抗一线治疗晚期肝细胞癌患者，相较于索拉非尼，可显著延长患者的 PFS 和 OS，同时改善客观缓解率和至疾病进展时间等次要终点。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688180":"君实生物","BK1583":"高瓴概念","01877":"君实生物","BK0239":"医药制造","BK1515":"抗疫概念","BK1161":"生物科技"},"translate_title":"Junshi Biotech (01877): The marketing application for a new indication of toripalimab combined with bevacizumab for the first-line treatment of advanced hepatocellular carcinoma was accepted","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688180":1,"01877":1},"content_text":"智通财经APP讯，君实生物(01877)公布，近日，公司收到国家药品监督管理局核准签发的《受理通知书》，特瑞普利单抗(商品名：拓益®)联合贝伐珠单抗用于不可切除或转移性肝细胞癌患者的一线治疗的新适应症上市申请获得受理。本次新适应症上市申请主要基于 HEPATORCH 研究(NCT04723004)，该研究是一项多中心、随机、开放、阳性药对照的 III 期临床研究，旨在评估与标准治疗索拉非尼相比，特瑞普利单抗联合贝伐珠单抗一线治疗不可切除或转移性肝细胞癌的有效性和安全性。该研究由中国科学院院士、复旦大学附属中山医院樊嘉教授担任主要研究者，在全国 57 家临床中心开展。2024 年 6 月，HEPATORCH 研究的主要终点无进展生存期(以下简称“PFS”，基于独立影像评估)和总生存期(以下简称“OS”)达到方案预设的优效边界。研究结果显示，特瑞普利单抗联合贝伐珠单抗一线治疗晚期肝细胞癌患者，相较于索拉非尼，可显著延长患者的 PFS 和 OS，同时改善客观缓解率和至疾病进展时间等次要终点。特瑞普利单抗安全性数据与已知风险相符，未发现新的安全性信号。本研究的详细数据将在后续的国际学术大会上公布。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2452156191"}